Just remember the special tree barks that Novavax needs are limited for limited production. Manufacturing and supply chain will become problem again in the future.
Laduree
Posts (179)
FlyDubai Cancels 65 Boeing 737 MAX Orders
https://onemileatatime.com/news/flydubai-cancels-boeing-737-max-order/
https://onemileatatime.com/news/flydubai-cancels-boeing-737-max-order/
FlyDubai Cancels 65 Boeing 737 MAX Orders
Promising business future with selling boosters. Bad timing to release P3 data before Quadruple Witching day.
It’s still May. 3P Data will not be out till June. It could be any weekday in June. 3P should include both data from both adults and teens.
Just googled it, as of yesterday only 35.5% US population has been vaccinated. We are far away from herd immunity.
China EV will never be able to go beyond the domestic market. Tesla is leading and will lead for a few more years
Ref: Call Summarized by @PAC yahoo finance conversation —
Today's call again illustrated that the Novavax senior management team does not know how to:
- run a glitch-free conference call (lots of technical issues)
- effectively promote its products
- communicate with the investor community
- meet self-imposed deadlines
A great deal of the call seemed like they wanted to get it over with quickly. Low energy.
However, the only "real" negative was that things are being pushed 1 or 2 months down the road.
Here are the Pros and Cons I got from today's call:
PROS
- Far exceeded both EPS and Revenue expectations
- Nothing material has changed, except dates -- by a little, not much
- US Phase 3 results will be announced in Q2 (next few weeks)
- US FDA, UK MHRA, EU EMA filings in Q3 ("as early in the quarter as possible")
- Rolling reviews on-going /w CA, NZ, SK, WHO; all will happen in Q3
- 30-40M doses in stock (currently on shelves)
- All manufacturing sites in GMP manufacturing state
* "all problems at commercial scale have been resolved"
* producing about 35M doses / month currently (w/o SII)- expecting full operating cadence (150M/mo) in Q4 (deferred from Q3)
- supply shortages to go away soon
- CMC has progressed with all regulatory agencies
- EU purchase agreement in progress
- "Best in class" efficacy, tolerance, manufacturing process, partners, multivalence, etc
- Development underway for both single and bivalent variant doses
- Clinical trials begin later this year for combo Flu/Covid dose
* animal studies already show same efficacy as individual shots - NVAX is considered the "booster candidate" for all current vaccines
- Phase 3 trials of Malaria vaccine scheduled in 4 African countries this year
- Supply agreements already in progress for 2022 and beyond
- "Demand for our vaccines is here to stay"
- $2B in bank
- Compelling future
CONS
- US PREVENT-19 trial results deferred due to 60% dropouts (dropouts slowed by initiating crossover ...which deferred trial results)
- Other EUAs also deferred to Q3 ("as early in quarter as possible")
- 150M/mo goal moved from Q3 to Q4 due to shortage of raw materials
- No mention of when NanoFlu goes into arms
- No mention of why Texas production hasn't started
- Flu/Covid combo vaccine not broadly in arms until after 2022
OTHER
- The UK strain now represents of 60% of USA infections
SUMMARY
Stan: "Every quarter gets more data, pointing to a successful vaccine. We're getting close to the end ...which is really the beginning for us ... we've eliminated all of the serious hurdles"
Doesn’t India have OCGN ??
Still a weak stock with all good news.